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Abstract
AIM: To determine the effect of pioglitazone, a specific
peroxisome proliferator-activated receptor- (PPAR)
ligand, on the development of acute pancreatitis (AP) and
on the expression of heat shock protein 70 (HSP70) in
the pancreas.
METHODS: AP was induced in rats by subcutaneous
infusion of cerulein for 5 h. Pancreatic blood flow was
measured by laser Doppler flowmetry. Plasma lipase
activity, interleukin-1 (IL-1) and IL-10 were determined.
Pancreatic weight and histology were evaluated and
pancreatic DNA synthesis and blood flow as well as
pancreatic mRNA for IL-1 and HSP70 were assessed in
rats treated with pioglitazone alone or in combination with
cerulein.
RESULTS: Pioglitazone administered (10-100 mg/kg i.g.)
30 min before cerulein, attenuated dose-dependently
the pancreatic tissue damage in cerulein-induced
pancreatitis (CIP) as demonstrated by the improvement
of pancreatic histology, reduction in plasma lipase activity,
plasma concentration of pro-inflammatory IL-1 and its
gene expression in the pancreas and attenuation of the
pancreatitis-evoked fall in pancreatic blood flow. CIP
increased pancreatic HSP70 mRNA and protein expression
in the pancreas and this effect was enhanced by pioglitazone
treatment.
CONCLUSION: Pioglitazone attenuates CIP and the
beneficial effect of this pioglitazone is multifactorial
probably due to its anti-inflammatory activities, to the
suppression of IL-1 and to the overexpression of HSP70.
PPAR ligands could represent a new therapeutic option
in the treatment of AP.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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Acute pancreatitis (AP) is associated with high morbidity
and mortality. Approximately 25% of patients develop
severe inflammation with pancreatic and peripancreatic fat
necrosis that requires intensive care. AP is a multifactorial
disease associated with the release of digestive enzymes to
the pancreatic interstitium and to the systemic circulation
as well as with the increased cytokine production and release,
which can ultimately lead to deleterious local and systemic
effects[1].
In general, the pathomechanism of AP is still poorly
understood. Recently, the modulatory role of peroxisome
proliferator-activated receptors (PPARs) has been proposed
in the inflammatory response of different organs[2]. The
PPAR family consists of  at least three different isoforms;
PPAR, PPAR, and PPAR[3]. PPAR is predominantly
detected in adipose tissue, but it is also expressed in other
tissues, including pancreatic tissue. When activated by a
specific ligand, PPARs heterodimerize with retinoid X
receptor and then bind to peroxisome proliferator response
element leading to the change in the transcription of target
genes involved in lipid metabolism, glucose homeostasis,
cell proliferation and differentiation, and inflammatory
response. PPARs are activated by natural ligands such
as fatty acids, eicosanoids, oxidized fatty acids, and by
pharmacological compounds such as glitazones. Pioglitazone
is a member of glitazones and it has been clinically used to
increase the sensitivity to insulin[4].
Several reports have demonstrated an anti-inflammatory
action of  the specific ligands of  PPAR. Activators of
PPAR inhibit the generation of  pro-inflammatory cytokines
such as interleukin-1 (IL-1), tumor necrosis factor-
(TNF-) and interleukin-6[5] and this effect seems to be
dependent on the inhibition of nuclear factor-B (NFB)
pathway[6].
Heat shock-proteins (HSPs) are a group of cytoprotective
proteins that help to maintain the metabolic and structural
integrity of cells. HSPs are produced in many cell types in
response to a variety of stresses, including heat, free radicals,
and toxins[7]. HSPs are highly conserved proteins and play
essential functions in protein folding, transport, translocation,
degradation, and assembly[8]. In the pancreas, HSPs have
been shown to provide the protection against cerulein- and
arginine-induced pancreatitis[9,10]. HSP70 (also referred as
HSP72 or inducible HSP70) is perhaps the most well-studied
member of  HSPs. However, it is not known whether PPAR
ligands interact with HSP70 and what is the biological
consequence of this potential interaction.
The aim of  the present study was: (1) to determine the
effect of  pioglitazone, a specific PPAR ligand, on the
development of acute cerulein-induced pancreatitis (CIP);
(2) to assess the effect of treatment with pioglitazone on
pancreatic expression of HSP70; and (3) to evaluate the
effect of pre-treatment with pioglitazone on pancreatic
synthesis and plasma level of IL-1.
MATERIALS AND METHODS
Experimental model of pancreatitis
Studies were performed on male Wistar rats weighing
150-200 g, in accordance with the experimental protocol
approved by the Committee for Research and Animal
Ethics of Jagiellonian University College of Medicine,
Cracow, Poland. Animals were housed in cages under
standard conditions, on a commercial pellet chow, at room
temperature with a 12-h light-dark cycle. Prior to the start
of experiments, rats were deprived of food, while drinking
water was available ad libitum. AP was induced by cerulein
that was diluted in saline and infused subcutaneously (s.c.)
for 5 h at a dose 10 g/kg/h as described earlier[11].
To study the effect of  pioglitazone on the development
of AP, the rats were divided into following groups: (1) rats
infused with 0.9% vehicle saline s.c. for 5 h (control); (2)
rats infused with 0.9% saline s.c. for 5 h and pretreated
with pioglitazone (10-100 mg/kg i.g., 30 min before saline
infusion); (3) rats infused with cerulein (10 g/kg/h) s.c. for
5 h; and (4) rats infused with cerulein (10 g/kg/h) s.c. for
5 h and pretreated with pioglitazone (10-100 mg/kg i.g., 30 min
before cerulein infusion). Animals were anesthetized and
killed after 5 h of saline or cerulein infusion. This particular
dose of pioglitazone 50 mg/kg was used because, in our
previous studies, similar dose was highly effective in speeding
up of the healing rate of gastric ulcer[12].
Determination of pancreatic blood flow
Following the infusion of  saline or cerulein, animals were
anesthetized with ketamine (50 mg/kg i.p., Bioketan,
Biowet, Gorzów, Poland) and the abdomen was opened.
The pancreas was exposed for the measurement of the
blood flow by laser Doppler flowmeter, using PeriFlux 4001
Master monitor (Perimed AB, Järfälla, Sweden) as described
previously[13]. The pancreatic blood flow was presented as
percent change from the value obtained in rats infused with
saline.
Determination of plasma lipase, IL-1, and IL-10 concentration
Immediately after the measurement of pancreatic blood
flow, the abdominal aorta was exposed and blood was taken
for the determination of  plasma lipase activity, and plasma
IL-1 and IL-10 concentrations as described before[14].
Plasma lipase activity was determined with a Kodak
Ectachem DT II System analyzer (Eastman Kodak Company,
Rochester, NY, USA). The values of plasma lipase activity
were expressed as units per liter.
The values of plasma IL-1 and IL-10 were measured
in duplicate, using the Biosource Cytoscreen rat IL-1 and
IL-10 kit based on a solid phase sandwich ELISA (BioSource
International Inc., Camarillo, CA, USA) according to the
manufacturer’s instructions. Concentrations were expressed
as picogram per milliliter.
Histological examination
After the collection of blood samples, the pancreas was
dissected out and divided into samples for analysis of
pancreatic mRNA, pancreatic protein, measurement of
pancreatic DNA synthesis, and histological examination.
Samples of pancreatic tissue for histological examination
were fixed in 40 g/L formaldehyde and stained with
hematoxylin and eosin. The histologic grading of edema
was made using a scale ranging from 0 to 3; 0 = no edema,
1 = interlobular edema, 2 = interlobular edema and moderate
intralobular edema, and 3 = interlobular edema and severe
intralobular edema. Leukocytic infiltration was graded from
0 (absent) to 3 for maximal alterations (diffuse infiltration
in the entire pancreatic gland). Grading of vacuolization
was based on the appropriate percentage of cell involved;
0 = absent, 1 = less than 25%, 2 = 25-50%, and 3 = more
than 50%.
Determination of pancreatic DNA synthesis
The rate of DNA synthesis in samples of pancreatic tissue
was determined as described previously[15]. Briefly, the
minced pancreatic tissue was incubated at 37 ℃ for 45 min
in 2 mL of medium containing 8 Ci/mL of [3H]thymidine
([6-3H]thymidine, 20-30 Ci/mmoL; Institute for Research,
Production and Application of Radioisotopes, Prague, Czech
Republic). DNA concentration was determined by the Giles
and Myers[16] procedure. The incorporation of mL [3H]
thymidine into DNA was determined by counting 0.5 mL
DNA-containing supernatant in a liquid scintillation system.
DNA synthesis was expressed as [3H]thymidine disintegrations
per minute per microgram DNA.
Determination of pancreatic mRNA for IL-1 and HSP70
Samples of pancreatic tissue for reverse transcriptase-
polymerase chain reaction (RT-PCR) were snap-frozen in
liquid nitrogen, and then stored at -80 ℃ until the time of
RNA extraction. Total RNA was extracted from the
pancreatic samples using the extraction kit from Stratagene
(Heidelberg, Germany). Following precipitation, RNA was
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resuspended in RNAse-free water and its concentration was
estimated by absorbance at 260 nm wavelength. RNA
samples were stored at -80 ℃ until analysis.
Single stranded cDNA was generated from 5 g of total
cellular RNA using Moloney murine leukemia virus reverse
transcriptase (Stratagene, Heidelberg, Germany) and
oligo-(dT)-primers (Stratagene, Heidelberg, Germany) in
accordance with the procedure described by our group
previously[17]. The resultant cDNA (2 L) was amplified in
50 L reaction volume containing 2 U Taq polymerase,
dNTP (200 mol/L each), 1.5 mmol/L MgCl2, 5 L 10×
PCR buffer (100 mmol/L KCl, 20 mmol/L Tris-HCl,
pH 8.3) and specific primers used at a final concentration
of  1 mmol/L (all reagents were obtained from Takara,
Shiga, Japan). The reaction mixture was amplified in a DNA
thermal cycler (Perkin-Elmer-Cetus, Norwalk, CT, USA)
and the incubation and thermal cycling conditions were as
follows: denaturation at 94 ℃ for 1 min, annealing at 60 ℃
for 45 s and extension at 72 ℃ for 2 min. The number of
cycles was 28 for GAPDH, 30 for HSP70, and 33 for
IL-1. The nucleotide sequence of the primers for GAPDH,
IL-1, and HSP70 were based on the sequences of the
published cDNAs as described previously[18,19]. The primer
sequence for IL-1 was: sense 5’-GCT ACC TAT GTC
TTG CCC GT-3’; antisense 5’-GAC CAT TGC TGT TTC
CTA GG-3’. Primer pair for IL-1 produced a 543-bp
product according to the cDNA sequence. The primer
sequence for HSP70 was: sense 5’-GTG AAG ATC TGC
GTC TGC TTG-3’; antisense 5’-TTTGACAACAGG
CTGGTG AAC C-5’. The expected length of  the product
was 590 bp. GAPDH primers were same as previously
published by our group[17]. All primers were synthesized
by GIBCO BRL/Life Technologies (Eggenstein, Germany).
PCR products were detected by electrophoresis on a 1.5%
agarose gel containing ethidium bromide. Location of a
predicted product was confirmed by using 100-bp ladder
(Takara, Shiga, Japan) as a standard size marker.
Protein extraction and analysis of pancreatic HSP70 expression
by Western blot analysis
Shock frozen tissue from rat pancreas was homogenized in
a lysis buffer (100 mmol/L Tris-HCl, pH 7.4, 15% glycerol,
2 mmol/L EDTA, 2% SDS, 100 mmol/L DDT) by the
addition of 1:20 dilution of aprotinin and 1:50 dilution of
100 mmol/L PMSF. Insoluble material was removed by
centrifugation at 12 000 g for 15 min. Approximately 50 µg
of total protein extracts were loaded on SDS-polyacrylamide
gels and run 40 mA, followed by transfer on nitrocellulose
membrane (Protran, Schleicher & Schuell, Germany) by
electroblotting. Three percent of BSA (Sigma-Aldrich,
Germany) in TBS/Tween-20 buffer (137 mmol/L NaCl,
20 mmol/L Tris-HCl, pH 7.4, 0.1% Tween-20) was used
to block filters for at least 1 h at room temperature. Specific
primary antibody against HSP70 (mouse monoclonal,
1:200 dilution; Stressgen Biotechnologies Corp., Canada),
or -actin (mouse monoclonal, dilution 1:5 000; Sigma-Aldrich,
Germany) was added to the membrane, followed by an
anti-mouse-IgG HRP conjugated secondary antibody
(dilution 1:20 000; Promega, USA) dissolved in 1% non-fat
milk in TBS-Tween-20 buffer. Incubation of  primary
antibody was followed by washing thrice with TBS-Tween-20
buffer for 10 min. Incubation of the secondary antibody
was followed by five washes for 10 min. Immunocomplexes
were detected by the SuperSignal West Pico Chemiluminescent
Kit (Pierce, USA). Thereafter, the developed membrane
was exposed to an X-ray film (Kodak, Wiesbaden, Germany).
Comparison between different treatment groups was made
by determining the examined protein/-actin ratio of  the
immunoreactive area by densitometry as described
elsewhere[18].
Statistical analysis
Comparison of the difference between the mean values of
various groups of experiments was made by analysis of
variance and the Student’s t-test for unpaired data. A
difference with a P value of less than 0.05 was considered
statistically significant. Results are expressed as mean±SE.
RESULTS
Effects of pioglitazone on the development of cerulein-induced
pancreatitis and pancreatic blood flow
Four criteria were used to confirm the AP in rats infused
with cerulein at a total dose of 50 g/kg (10 g/kg/h s.c.
×5 h): macroscopic and microscopic signs of AP, pancreatic
edema leading to the increase in pancreatic weight and the
rise in serum lipase activities. All these criteria were fulfilled
in all rats treated with cerulein.
After the infusion of cerulein, the pancreas was enlarged
with a visible collection of edematous fluid and the pancreatic
mass was almost doubled (Figure 1). At light microscopic
level, profound interlobular and intralobular edema,
vacuolization of acinar cells, and moderate perivascular and
scare diffuse leukocyte infiltration were observed. In rats
pretreated with pioglitazone before the start of cerulein
infusion, the inflammatory changes in the pancreas were
significantly less pronounced when compared to changes
observed in rats treated with cerulein alone (Figure 2 and
Table 1). Treatment with pioglitazone alone had no effect
on morphological features of the pancreas.
Plasma lipase activity in control, saline-infused rats,
reached 57.0±6.0 U/L. In rats infused with cerulein, plasma
lipase activity was almost increased eightfold, compared to
the level obtained from control rats infused with saline. In
rats pretreated with pioglitazone before cerulein, a significant
and dose-dependent reduction in plasma lipase activity was
Table 1  Histology findings in the pancreas after treatment with
various doses of pioglitazone alone or in combination with cerulein
infused s.c. to induce pancreatitis
Edema        Leukocyte         Vacuolization
      infiltration        of acinar cells
Control      0               0          0
Pioglitazone 10 mg/kg      0               0          0
Pioglitazone 20 mg/kg      0               0          0
Pioglitazone 50 mg/kg      0               0          0
Pioglitazone 100 mg/kg      0               0          0
Cerulein       2/3               2            2/3
Pioglitazone 10 mg/kg+cerulein       2/3                  1/2          2
Pioglitazone 20 mg/kg+cerulein      2               1            0.5
Pioglitazone 50 mg/kg+cerulein       1/2                  0/1          1
Pioglitazone 100 mg/kg+cerulein      1               1          1
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found (Figure 3 and Table 2).
In saline-infused control rats, total pancreatic DNA
synthesis reached 58.8±1.6 dpm/g DNA (Figure 4).
Treatment with pioglitazone alone did not affect pancreatic
DNA synthesis in animals infused with saline. The induction
of AP by cerulein was associated with a significant fall in
DNA synthesis in the pancreas for about 44%. This effect
was partly, but significantly reversed by the treatment with
pioglitazone.
Pancreatic blood flow measured in rats with CIP was
reduced by about 40% as compared to the control group
(Figure 5). Treatment with pioglitazone did not affect
pancreatic blood flow in animals infused with vehicle saline.
In contrast, in rats given a cerulein infusion, pretreatment
with pioglitazone was associated with a significant reverse
in the cerulein-induced fall in the pancreatic blood flow.
Figure 1  Pancreatic weight in rats with or without CIP pretreated with saline or
pioglitazone at a dose 50 mg/kg. Mean±SE of eight rats in each experimental
group. Asterisk indicates a significant change as compared to the value in rats
infused with saline. Cross indicates a significant change as compared to rats
with CIP alone. aP<0.05 vs CIP alone.
Figure 2  Histological changes (edema, infiltration, and vacuolization) observed in
rats with or without CIP and pretreated with saline or pioglitazone at a dose 50 mg/
kg. Mean±SE of eight rats in each experimental group. Asterisk indicates a
significant change as compared to the value in rats infused with saline. Cross
indicates a significant change as compared to rats with CIP alone.aP<0.05 vs CIP alone.
Table 2  Pancreatic DNA synthesis, pancreatic blood flow, plasma lipase activity, and the levels of IL-1 and IL-10 in rats treated with various
doses of pioglitazone alone or in combination with cerulein infused s.c. to induce pancreatitis
          Pancreatic DNA Pancreatic blood  Plasma lipase             Plasma IL-1    Plasma IL-10
synthesis (dpm/g DNA)                  flow (% of control) activity (U/L) (pg/mL)          (pg/mL)
Control 58.8±1.6            100±2.0        57.0±6.0 70.3±4.2          67.0±5.0
Pioglitazone 10 mg/kg 61.3±1.9           98.9±1.7        62.3±5.6 69.7±3.9          66.9±4.1
Pioglitazone 20 mg/kg 60.9±2.2           99.6±2.1        59.2±6.7 74.2±5.5          72.7±5.1
Pioglitazone 50 mg/kg 61.6±1.1        101.5±1.7        60.5±4.5 68.2±4.9          73.0±3.0
Pioglitazone 100 mg/kg 57.4±2.1           97.6±2.4        71.8±6.9 76.8±5.4          71.9±5.1
Cerulein 33.8±1.4a           60.9±2.5a      400.3±10.6a                 212.0±8.6a          79.2±3.5
Pioglitazone 10 mg/kg+cerulein 37.6±2.8a           66.2±2.1a      372.1±12.1a                 198.4±5.7a          73.1±3.8
Pioglitazone 20 mg/kg+cerulein 41.6±1.7a,c           69.3±1.5a,c      322.4±9.6a,c                 153.2±6.2a,c          81.6±7.2
Pioglitazone 50 mg/kg+cerulein 45.9±1.7a,c           79.2±2.2a,c      288.3±18.0a,c                 131.3±7.2a,c          75.1±3.0
Pioglitazone 100 mg/kg+cerulein 39.6±2.3a           65.1±2.3a      269.3±13.9a                 129.3±6.9a          64.6±3.2
aP<0.05 vs control, cP<0.05 vs cerulein alone.
Figure 3  Plasma lipase activity in rats with or without CIP and pretreated with
saline or pioglitazone at a dose 50 mg/kg. Mean±SE of eight rats in each
experimental group. Asterisk indicates a significant change as compared to the
value in rats infused with saline. Cross indicates a significant change as compared
to rats with CIP alone. aP<0.05 vs CIP alone.
Figure 4  Pancreatic DNA synthesis in rats with or without CIP and pretreated
with saline or pioglitazone at a dose 50 mg/kg. Mean±SE of eight rats in each
experimental group. Asterisk indicates a significant change as compared to the
value in rats infused with saline. Cross indicates a significant change as compared






































































































 Konturek PC et al. Pioglitazone and acute pancreatitis                        6325
The measurement of plasma level of IL-10 showed
no significant changes in rats with CIP or treated with
pioglitazone as compared to control group (Figure 6). In
contrast, IL-1 was significantly increased in rats with CIP.
Pretreatment with pioglitazone did not significantly affect
plasma IL-1 concentration in rats infused with saline,
but pretreatment with pioglitazone caused a significant and
dose-dependent reduction in plasma level of this important
pro-inflammatory cytokine in animals with CIP.
In tissue samples taken from control pancreas without
CIP, a weak but detectable signal for IL-1 mRNA was
observed (Figure 7). The expression of  GAPDH was well
preserved in all the samples. After the induction of  CIP, a
significant increase in IL-1 mRNA was found. This effect
was strongly attenuated in rats pretreated with pioglitazone.
The analysis of mRNA expression of HSP70 showed a
detectable signal of HSP70 in  the samples of the pancreas
obtained from control group (Figure 8). After the induction
of CIP, a strong upregulation of mRNA for HSP70 was
observed. Interestingly, the treatment with pioglitazone
caused a further increase in mRNA expression for HSP70.
At the protein level, similar results were observed; a
weak signal for HSP70 in control pancreas, a significant
increase of the signal in CIP, and a further increase in HSP70
expression in rats with CIP pretreated with pioglitazone
(Figure 9).
DISCUSSION
We have reported in this study that the pre-treatment of
rats with pioglitazone, a specific PPAR ligand, significantly
and dose-dependently attenuated the development of CIP.
This result is in accordance with the earlier report that
natural PPAR ligand, 15d-PGJ2, reduced the severity of
CIP[19]. The mechanisms underlying the protective effect
of pioglitazone on the CIP remain unclear. First of all, the
beneficial effect of pioglitazone on the pancreas subjected
to acute injury by cerulein over-stimulation could be due
to its local and systemic anti-inflammatory properties.
Previous reports indicated that PPAR agonists exhibit anti-
inflammatory effects both in in vitro and in vivo studies[5,19].
This anti-inflammatory effect seems to be related to multiple
mechanisms. Ricote et al.[20], demonstrated that PPAR
ligands inhibit macrophage activation and inflammatory
cytokine production. Our previous studies showed that
pioglitazone reduces acute and chronic gastric mucosal lesions
due to the inhibition of TNF- and IL-1 expression[12].
Furthermore, Meier et al.[21], showed that PPAR ligands
exert anti-inflammatory activity by inducing the production
Figure 6  Plasma IL-1 and IL-10 levels in rats with or without CIP and
pretreated with saline or pioglitazone at a dose 50 mg/kg. Mean±SE of eight rats
in each experimental group. Asterisk indicates a significant change as compared
to the value in rats infused with saline. Cross indicates a significant change as
compared to rats with CIP alone.aP<0.05 vs CIP alone.
Figure 5  Pancreatic blood flow in rats with or without CIP and pretreated with
saline or pioglitazone at a dose 50 mg/kg. Mean±SE of eight rats in each
experimental group. Asterisk indicates a significant change as compared to the
value in rats infused with saline. Cross indicates a significant change as compared
to rats with CIP alone.aP<0.05 vs CIP alone.
Figure 7  Expression of IL-1 mRNA and densitometric analysis of IL-1
mRNA expression (IL-1/GAPDH ratio) in rats infused with saline without
pancreatitis (control), rats with CIP and rats with CIP pretreated with pioglitazone.
(A,B) Asterisk indicates a significant change  as compared to the value in rats
infused with saline. Cross indicates a significant change as compared to rats
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of IL-1 receptor antagonist. One of the important mechanisms
by which pioglitazone inhibits the inflammatory reaction is
the reduction in activation of the transcription factor, NFB,
by the IB-dependent mechanism[19]. Moreover, Imamoto
et al.[22], found that pioglitazone exerts a strong inhibitory
effect on the expression of adhesion molecule VCAM-1
on neutrophils and endothelial cells, thus reducing the
leukocyte recruitment in the inflamed tissue. There is also
clinical evidence for the anti-inflammatory effects of
glitazones. Haffner et al.[23], reported that treatment of type
2 diabetes mellitus patients with rosiglitazone resulted in a
reduction of serum concentration of C-reactive protein
and WBCs count. All these reports underline the importance
of  PPAR ligands in the modulation of  inflammatory
reaction in different organs, particularly in reducing the
cerulein-induced oxidative stress in pancreatic tissue[24].
Our present study confirms and extends previous
findings[25-27] by showing that inflammatory infiltration
of pancreatic tissue caused by CIP is accompanied by a
significant increase in pancreatic mRNA expression of
IL-1 and increased release of this cytokine in rats infused
for 5 h with supramaximal dose of cerulein. The new finding
of our present study is that pretreatment with pioglitazone
at a dose of 50 mg/kg significantly suppresses the gene
expression and plasma level of IL-1, as well as reduces
leukocyte infiltration of pancreatic tissue in the course of
CIP. This observation indicates that pioglitazone, a specific
PPAR ligand, is a powerful modulator of  inflammatory
response.
In contrast to IL-1, IL-10 is found to be a major anti-
inflammatory cytokine[28].  It reduces activation of
macrophages and inhibits the production of reactive oxygen
species and pro-inflammatory cytokines[28]. Van Laethem
et al.[29], showed that administration of IL-10 before and
during the induction of AP decreases the severity of this
pancreatitis. Also, administration of some growth factor
such as hepatocyte growth factor[30] or insulin-like growth
factor-1[13] increases a plasma level of IL-10 and inhibits
the development of AP. In our present study, we did not
observe any alteration in plasma IL-10 concentration
after the development of acute CIP or pretreatment with
pioglitazone at various doses. This result suggests that the
anti-inflammatory action of pioglitazone does not depend
upon the release of IL-10.
The most important finding of this study is the observation
that pioglitazone increased significantly the expression of
HSP70. HSPs are highly conserved cytoprotective proteins
that have essential functions in protein folding, transport,
degradation, and assembly. HSPs are classified into six major
families (small HSP, HSP40, HSP60, HSP70, HSP90, and
HSP100) depending on their molecular weight[7]. HSP70 is
the best studied member of HSPs family. Previous studies
demonstrated that both thermal and non-thermal stress
protects against CIP and prevents trypsinogen activation in
the pancreas and this effect is mediated by HSP70[31]. The
potential protective mechanisms of HSPs on pancreas
Figure 8  Expression of HSP70 mRNA and densitometric analysis of HSP70
mRNA expression (HSP70/GAPDH ratio) in rats infused with saline without
pancreatitis (control), rats with CIP and rats with CIP pretreated with pioglitazone.
(A,B) Asterisk indicates a significant change as compared to the value in rats
infused with saline. Cross indicates a significant change as compared to rats
with CIP alone.aP<0.05 vs CIP alone.
Figure 9  Expression of HSP70 protein and densitometric analysis of HSP70
protein expression (HSP70/-actin ratio) in rats infused with saline without
pancreatitis (control), rats with CIP and rats with CIP pretreated with pioglitazone.
(A,B) Asterisk indicates a significant change as compared to the value in rats
infused with saline. Cross indicates a significant change as compared to rats




















































include: stabilization and refolding of damaged proteins,
resistance of the cells to apoptosis or necrosis, decrease in
the level of pro-inflammatory cytokines and antioxidant effects
and interference with intra-acinar zymogen activation[7,31-33].
Our results are in accordance with the previous studies
showing an increase of HSP70 at mRNA and protein
level after induction of CIP. The major finding is,
however, the observation of  the further increase in HSP70
expression in rats pretreated with pioglitazone. This indicates
that the protective effects of pioglitazone could be mediated,
at least in part, through increased HSP expression. This
issue needs to be clarified in further studies, especially in in
vitro studies.
Administration of pioglitazone alone did not affect
pancreatic DNA synthesis. Induction of AP by cerulein
caused a reduction in the pancreatic DNA synthesis, that is
in agreement with our previous observation[34], and may be
considered as an index of pancreatic damage. In rats with
the induction of pancreatitis by cerulein, the pretreatment
with pioglitazone attenuated the pancreatitis-evoked fall in
pancreatic DNA synthesis. This observation is an additional
evidence of protective effect of pioglitazone against
pancreatic damage in CIP.
It is well known that the development of AP is associated
with the reduction in pancreatic blood flow[35-37], whereas
vasodilatation and the improvement of pancreatic blood
flow reduces the development of AP[37]. Our results are in
accordance with these observations. Administration of
cerulein induced acute edematous pancreatitis and reduced
the pancreatic blood flow. Pretreatment with pioglitazone
partly reversed cerulein-induced fall in pancreatic blood
flow, suggesting that the improvement of  pancreatic
microcirculation might contribute to the protective effect
of pioglitazone administration. The mechanism of vascular
effects of pioglitazone administration is unclear. Pioglitazone
given alone without cerulein infusion had no effect on
pancreatic blood flow. This observation indicates that
pioglitazone acts indirectly on pancreatic blood flow,
probably by the reduction of cerulein-induced pancreatic
edema and reduction of leukocyte activation.
The fact that pioglitazone strongly inhibits the inflammatory
reaction in CIP, suggests that this compound may offer a
new treatment opportunity, especially in the prophylaxis of
pancreatitis in human beings. This issue should be studied
in the prospective protocol in human beings. Moreover,
the protective effect of pioglitazone should be checked in
other acute and chronic experimental models of pancreatitis.
In summary, our study provides evidence that pioglitazone,
a specific PPAR ligand, ameliorates significantly the
pancreatic damage associated with the CIP confirmed by
the improvement of  pancreas histology and the reduction
in plasma lipase activity. Treatment with pioglitazone
significantly inhibited the production and release of IL-1
and enhanced the expression of pancreatic HSP70. These
observations indicate that the treatment with pioglitazone
may offer a new therapeutic option in the treatment or
prophylaxis of pancreatitis.
REFERENCES
1 Kingsnorth A. Role of cytokines and their inhibitors in acute
pancreatitis. Gut 1997; 40: 1-4
2 Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-
activated receptors and inflammation: from basic science to
clinical applications. Int J Obes Relat Metab Disord 2003; 27
(Suppl 3): S41-45
3 Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G,
Umesono K, Blumberg B, Kastner P, Mark M, Chambon P,
Evans RM. The nuclear receptor superfamily: the second
decade. Cell 1995; 83: 835-839
4 Berger J, Moller DE. The mechanisms of action of PPARs.
Annu Rev Med 2002; 53: 409-435
5 Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit
production of monocyte inflammatory cytokines. Nature 1998;
391: 82-86
6 Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh
SA, Flanigan A, Murthy S, Lazar MA, Wu GD. A novel therapy
for colitis utilizing PPAR-gamma ligands to inhibit the epi-
thelial inflammatory response. J Clin Invest 1999; 104: 383-389
7 Rakonczay Z, Takacs T, Boros I, Lonovics J. Heat shock pro-
teins and the pancreas. J Cell Physiol 2003; 195: 383-391
8 Parcellier A, Gurbuxani S, Schmitt E, Solary E, Garrido C.
Heat shock proteins, cellular chaperones that modulate mito-
chondrial cell death pathways. Biochem Biophys Res Commun
2003; 304 : 505-512
9 Wagner AC, Weber H, Jonas L, Nizze H, Strowski M, Fiedler F,
Printz H, Steffen H, Goke B. Hyperthermia induces heat shock
protein expression and protection against caerulein-induced
pancreatitis in rats. Gastroenterology 1996; 111: 1333-1342
1 0 Tashiro M, Ernst SA, Edwards J, Williams JA. Hyperthermia
induces multiple pancreatic heat shock proteins and protects
against subsequent arginine-induced acute pancreatitis in rats.
Digestion 2002; 65: 118-126
1 1 Konturek PC, Jaworek J, Maniatoglou A, Bonior J, Meixner
H, Konturek SJ, Hahn EG. Leptin modulates the inflamma-
tory response in acute pancreatitis. Digestion 2002; 65: 149-160
1 2 Konturek PC, Brzozowski T, Kania T, Konturek SJ, Kwiecien
S, Pajdo R, Hahn EG. Pioglitazone, a specific ligand of per-
oxisome proliferator-activated receptor-gamma, accelerates
gastric ulcer healing in rats. Eur J Pharmacol 2003; 38: 468-476
1 3 Konturek SJ, Szlachcic A, Dembinski A, Warzecha Z, Jaworek
J, Stachura J. Nitric oxide in pancreatic secretion and hor-
mone-induced pancreatitis in rats. Int J Pancreatol 1994; 15:
19-28
1 4 Warzecha Z, Dembinski A, Ceranowicz P, Konturek SJ,
Tomaszewska R, Stachura J, Konturek PC. IGF-1 stimulates
production of interleukin-10 and inhibits development of
caerulein-induced pancreatitis. J Physiol Pharmacol 2003; 54:
575-590
1 5 Warzecha Z, Dembinski A, Konturek PC, Ceranowicz P,
Konturek SJ. Epidermal growth factor protects against pan-
creatic damage in cerulein-induced pancreatitis. Digestion
1999; 60 : 314-323
1 6 Giles KW, Myers A. An improvement diphenylamine method
for the estimation of deoxyribonucleic acid. Nature 1965; 206: 93
1 7 Warzecha Z, Dembinski A, Ceranowicz P, Konturek S,
Tomaszewska R, Stachura J, Nakamura T, Konturek PC. In-
hibition of cyclooxygenase-2 reduces the protective effect of
hepatocyte growth factor in experimental pancreatitis. Eur J
Pharmacol 2004; 486: 107-119
1 8 Konturek PC, Brzozowski T, Kania J, Konturek SJ, Hahn EG.
Nitric oxide-releasing aspirin protects gastric mucosa against
ethanol damage in rats with functional ablation of sensory
nerves. Inflamm Res 2003; 52: 359-365
1 9 Hashimoto K, Ethridge RT, Saito H, Rajaraman S, Evers BM.
The PPARgamma ligand, 15d-PGJ2, attenuates the severity
of cerulein-induced acute pancreatitis. Pancreas 2003; 27: 58-66
2 0 Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxi-
some proliferator-activated receptor-gamma is a negative
regulator of macrophage activation. Nature 1998; 391: 79-82
2 1 Meier CA, Chicheportiche R, Juge-Aubry CE, Dreyer MG,
Dayer JM. Regulation of the interleukin-1 receptor antagonist
in THP-1 cells by ligands of the peroxisome proliferator-acti-
 6328      ISSN 1007-9327     CN 14-1219/ R   World J Gastroenterol    October 28, 2005   Volume 11   Number 40
vate receptor gamma. Cytokine 2002; 18: 320-328
2 2 Imamoto E, Yoshida N, Uchiyama K, Kuroda M, Kokura S,
Ichikawa H, Naito Y, Tanigawa T, Yoshikawa T. Inhibitory
effect of pioglitazone on expression of adhesion molecules on
neutrophils and endothelial cells. Biofactors 2004; 20: 37-47
2 3 Haffner SM, Greenberg AS, Weston WM, Chen H, Williams
K, Freed MI. Effect of rosiglitazone treatment on nontradi-
tional markers of cardiovascular disease in patients with type
2 diabetes mellitus. Circulation 2002; 106: 679-684
2 4 Fu K, Sarras MP, De Lisle RC, Andrews GK. Expression of
oxidative stress-responsive genes and cytokine genes during
caerulein-induced acute pancreatitis. Am J Physiol 1997; 273:
G696-G705
2 5 Norman JG, Fink GW, Denham W. Tissue-specific cytokine
production during experimental acute pancreatitis. A prob-
able mechanism for distant organ dysfunction. Dig Dis Sci
1997; 42 : 1783-1788
2 6 Warzecha Z, Dembinski A, Ceranowicz P. Calcitonin gene-
related peptide can attenuate or augment pancreatic damage
in caerulein-induced pancreatitis in rats. J Physiol Pharmacol
1999; 50 : 49-62
2 7 Moore KW, O’Garra A, de Waal  Malefyt  R, Vieira  P,
Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11 :
165-190
2 8 de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de
Vries JE. Interleukin-10 (IL-10) inhibits cytokine synthesis by
human monocytes: an autoregulatory role of IL-10 produced
by monocytes. J Exp Med 1991; 174: 1209-1220
2 9 Van Laethem JL, Marchant A, Delvaux A, Goldman M,
Robberecht P, Velu T, Deviere J. Interleukin 10 prevents ne-
crosis in murine experimental acute pancreatitis. Gastroenter-
ology 1995; 108: 1917-1922
3 0 Warzecha Z, Dembinski A, Konturek PC, Ceranowicz P,
Dembinski M, Stachura J, Konturek SJ. Hepatocyte growth
factor attenuates pancreatic damage in caerulein-induced
pancreatitis. Eur J Pharmacol 2001; 430: 113-121
3 1 Frossard JL, Bhagat L, Lee HS, Hietaranta AJ, Singh VP,
Song AM, Steer ML, Saluja AK. Both thermal and non-ther-
mal stress protect against caerulein induced pancreatitis and
prevent trypsinogen activation in the pancreas. Gut 2002; 50:
78-83
3 2 Takayama S, Reed JC, Homma S. Heat-shock proteins as
regulators of apoptosis. Oncogene 2003; 22: 9041-9047
3 3 Bhagat L, Singh VP, Hietaranta AJ, Agrawal S, Steer ML,
Saluja AK. Heat shock protein 70 prevents secretagogue-in-
duced cell injury in the pancreas by preventing intracellular
trypsinogen activation. J Clin Invest 2000; 106: 81-89
3 4 Dembinski A, Warzecha Z, Konturek PC, Ceranowicz P,
Konturek SJ, Tomaszewska R, Stachura J. Adaptation of pan-
creas to repeated caerulein-induced pancreatitis in rats. J
Physiol Pharmacol 1996; 47: 455-467
3 5 Menger MD, Plusczyk T, Vollmar B. Microcirculatory de-
rangements in acute pancreatitis. J Hepatobiliary Pancreat Surg
2001; 8: 187-194
3 6 Zhou ZG, Chen YD, Sun W, Chen Z. Pancreatic microcircula-
tory impairment in experimental acute pancreatitis in rats.
World J Gastroenterol 2002; 8: 933-936
3 7 Warzecha Z, Dembinski A, Ceranowicz P, Konturek PC,
Stachura J, Konturek SJ, Niemiec J. Protective effect of calci-
tonin gene-related peptide against caerulein-induced pancre-
atitis in rats. J Physiol Pharmacol 1997; 48: 775-787
Science Editor Guo SY  Language Editor Elsevier HK
 Konturek PC et al. Pioglitazone and acute pancreatitis                        6329
